Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Spiriva
Generic Name
Tiotropium Bromide
Active Ingredient
TiotropiumCategory
Other
Salt Form
Bromide Monohydrate
Variants
3
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 18 ug/1 | CAPSULE | ORAL, RESPIRATORY (INHALATION) | 0597-0075 |
| 18 ug/1 | CAPSULE | ORAL, RESPIRATORY (INHALATION) | 50090-7645 |
| 18 ug/1 | CAPSULE | ORAL, RESPIRATORY (INHALATION) |
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Spiriva, you must consult a qualified healthcare professional.
Detailed information about Spiriva
Tiotropium is a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of COPD and asthma. It works by relaxing the muscles in the airways to improve breathing and prevent bronchospasm.
Dosage for tiotropium depends strictly on the device being used and the condition being treated.
Tiotropium is not approved for use in children under the age of 6 for any condition.
Because tiotropium is primarily excreted by the kidneys, patients with moderate to severe renal impairment (Creatinine Clearance < 50 mL/min) should be monitored closely. While there is no specific 'reduced dose' protocol, the risk of anticholinergic side effects increases as kidney function declines. Healthcare providers may choose alternative therapies if renal function is significantly compromised.
No dosage adjustment is typically required for patients with liver disease, as hepatic metabolism plays a minor role in the clearance of tiotropium.
No dosage adjustment is generally required based solely on age. However, elderly patients are more likely to have decreased renal function and a higher sensitivity to anticholinergic effects (like confusion or urinary retention), so caution is advised.
Proper technique is critical for the effectiveness of tiotropium.
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and return to your regular schedule. Never take two doses at once or more than one dose in a 24-hour period.
An overdose of inhaled tiotropium is unlikely to be life-threatening because of its low systemic absorption, but it can cause severe side effects. Signs of overdose include extreme dry mouth, blurred vision, rapid heart rate (tachycardia), confusion, and inability to urinate. If an overdose is suspected, contact a Poison Control Center or seek emergency medical attention immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop taking the medication without medical guidance, even if you feel better.
The most frequently reported side effect of tiotropium is dry mouth (xerostomia). This occurs because the medication blocks muscarinic receptors in the salivary glands. While usually mild, it can be persistent.
Other common side effects include:
These side effects may occur in a smaller percentage of patients:
Tiotropium is a maintenance medication and must not be used as a rescue medication for the treatment of acute episodes of bronchospasm (sudden breathing problems). Patients must always have a fast-acting rescue inhaler (like albuterol) available for sudden symptoms. If your breathing problems do not improve or if they get worse while using tiotropium, contact your healthcare provider immediately.
There are currently no FDA black box warnings for tiotropium bromide. It has a well-established safety profile when used as directed for its approved indications.
Patients with a severe hypersensitivity to milk proteins should not use the Spiriva HandiHaler. The capsules contain lactose monohydrate, which may contain trace amounts of milk protein. Inhaling these proteins can trigger a severe, life-threatening allergic reaction (anaphylaxis). The Spiriva Respimat (soft mist) does not contain lactose and may be an alternative for these patients, though a doctor's consultation is required.
Other Anticholinergic Medications: Tiotropium should not be used in combination with other anticholinergic-containing drugs. This includes:
Clinical Consequence: Using these together creates an 'additive effect,' significantly increasing the risk of systemic anticholinergic toxicity, including severe dry mouth, urinary retention, constipation, blurred vision, and potential cardiac arrhythmias. Management involves choosing one LAMA and avoiding 'double-dosing' with short-acting anticholinergics.
There are specific circumstances where tiotropium must never be used due to the risk of life-threatening complications:
FDA Pregnancy Category C: There are no adequate and well-controlled studies of tiotropium in pregnant women. Animal studies have shown some developmental toxicity at very high doses (inhalation doses much higher than the human equivalent).
It is not known whether tiotropium is excreted in human breast milk. However, because tiotropium is a quaternary ammonium compound, it is expected to be poorly absorbed if the infant ingests it via milk. Furthermore, the amounts reaching the mother's blood after inhalation are very low. Nonetheless, caution should be exercised, and nursing mothers should monitor their infants for signs of dry mouth or constipation.
Tiotropium is a long-acting, antimuscarinic agent, often referred to as an anticholinergic. In the airways, it exhibits pharmacological effects through inhibition of M3-receptors at the smooth muscle, leading to bronchodilation.
The competitive and reversible inhibition of muscarinic receptors by tiotropium prevents the binding of acetylcholine, the primary neurotransmitter of the parasympathetic nervous system. Acetylcholine normally causes bronchoconstriction and mucus secretion. By blocking this pathway, tiotropium keeps the airways open for an extended period. Its high 'kinetic selectivity' means it stays attached to the M3 receptors (which cause bronchodilation) much longer than the M2 receptors (which regulate acetylcholine release), providing a 24-hour therapeutic window.
Common questions about Spiriva
Tiotropium is primarily used as a long-term maintenance treatment for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema. It is also used as a maintenance treatment for asthma in adults and children 6 years of age and older. It works by keeping the airways open (bronchodilation) to make breathing easier and to prevent symptoms like wheezing and shortness of breath. It is important to note that tiotropium is a 'controller' medication and should not be used as a 'rescue' inhaler for sudden breathing attacks. Your doctor will likely prescribe a separate fast-acting inhaler for emergencies.
The most common side effect reported by patients taking tiotropium is dry mouth, which affects more than 10% of users. This occurs because the medication blocks the receptors that stimulate saliva production. Other frequent side effects include sore throat, cough, sinus pressure (sinusitis), and upper respiratory tract infections. Some patients may also experience constipation or a mild headache. Most of these side effects are mild and tend to diminish as your body adjusts to the medication, but you should discuss any persistent symptoms with your healthcare provider.
There is no known direct interaction between tiotropium and alcohol. However, it is generally advised to use alcohol in moderation if you have a respiratory condition like COPD or asthma. Alcohol can contribute to dehydration, which may worsen the dry mouth side effect caused by tiotropium. Additionally, heavy alcohol consumption can sometimes interfere with your breathing patterns or your ability to use your inhaler correctly. Always consult your doctor about your alcohol intake to ensure it does not interfere with your overall treatment plan.
Tiotropium is classified as FDA Pregnancy Category C, meaning there are no definitive studies in humans to confirm its safety. Animal studies have shown some potential for harm, but only at doses much higher than those used by humans. Doctors generally only prescribe tiotropium to pregnant women if the benefit of controlling their respiratory symptoms outweighs the potential risks to the baby. If you are pregnant or planning to become pregnant, it is essential to discuss your treatment options with your obstetrician and pulmonologist to ensure both your health and the baby's safety.
Tiotropium begins to work relatively quickly, with some bronchodilation occurring within 30 minutes of the first dose. However, because it is a long-acting maintenance medication, it may take 4 to 8 weeks of consistent, daily use to feel the full therapeutic benefits. It is designed to build up a steady level in your system to keep your airways open 24 hours a day. You should continue taking the medication every day as prescribed, even if you do not feel an immediate difference in your breathing.
You should not stop taking tiotropium suddenly without consulting your healthcare provider. Because it is a maintenance medication, stopping it will likely cause your COPD or asthma symptoms to return or worsen within a few days. While tiotropium does not cause a physical 'withdrawal' in the traditional sense, the loss of its bronchodilating effect can lead to increased shortness of breath and a higher risk of lung flare-ups. If you are experiencing side effects that make you want to stop, your doctor can help you transition to a different medication safely.
If you miss a dose of tiotropium, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, you should skip the missed dose and simply take the next one at your regular time. You should never take two doses at once or take more than the prescribed amount in a 24-hour period. Taking too much tiotropium increases the risk of side effects like severe dry mouth, blurred vision, or difficulty urinating. Setting a daily alarm can help you stay consistent with your dosing schedule.
Weight gain is not a recognized or common side effect of tiotropium. Clinical trials have not shown a significant link between the use of this medication and changes in body weight. If you experience unexplained weight gain while taking tiotropium, it may be due to other factors, such as other medications you are taking (like oral corticosteroids), changes in your activity level, or fluid retention related to heart or kidney issues. You should discuss any significant changes in your weight with your doctor to determine the underlying cause.
Tiotropium can be taken with many other medications, but it should not be combined with other anticholinergic drugs like ipratropium or glycopyrrolate, as this increases the risk of side effects. It is frequently prescribed alongside other respiratory treatments such as inhaled corticosteroids (like fluticasone) or long-acting beta-agonists (like salmeterol). However, you must inform your doctor about all the medicines you use, including over-the-counter drugs and herbal supplements, to avoid potential interactions that could affect how tiotropium works or increase your risk of toxicity.
Yes, generic versions of tiotropium bromide inhalation powder (the equivalent of Spiriva HandiHaler) have been approved by the FDA and are available in the United States. Generic medications must meet the same strict standards for safety, strength, and quality as the brand-name drug. The availability of a generic can often make the medication more affordable for patients. However, the delivery device for the generic may look or operate slightly differently than the brand-name version, so ensure you receive proper training from your pharmacist on how to use the specific device you are given.
Other drugs with the same active ingredient (Tiotropium)
Rare but documented side effects include:
While tiotropium is generally well-tolerated, some side effects require immediate medical intervention:
> Warning: Stop taking Tiotropium and call your doctor immediately if you experience any of these serious symptoms.
With prolonged use, the most significant concern is the cumulative 'anticholinergic burden.' In some patients, especially the elderly, long-term use of anticholinergics has been studied for potential links to cognitive changes or increased cardiovascular risk. However, for most patients with COPD, the benefits of improved lung function and reduced exacerbations outweigh these theoretical long-term risks. Regular dental checkups are recommended, as chronic dry mouth can increase the risk of dental cavities and oral thrush (candidiasis).
No FDA black box warnings for Tiotropium. Unlike some long-acting beta-agonists (LABAs) which previously carried warnings about asthma-related death, tiotropium (a LAMA) does not carry a black box warning. However, it is strictly indicated for maintenance and not for acute rescue.
Report any unusual symptoms to your healthcare provider. Monitoring your response to the medication helps your doctor ensure the treatment remains safe and effective for you.
Tiotropium should be used with extreme caution in patients with narrow-angle glaucoma. Because it is an anticholinergic, it can increase intraocular pressure (pressure within the eye), potentially worsening the condition or triggering an acute glaucoma attack. Patients should be instructed to avoid getting the powder or mist into their eyes.
Anticholinergic medications can decrease the contraction of the bladder muscle. Use tiotropium with caution if you have prostatic hyperplasia (enlarged prostate) or bladder-neck obstruction. It may cause or worsen urinary retention (difficulty passing urine).
While clinical trials (such as the TIOSPIR trial) have generally shown tiotropium to be cardiovascularly safe, some observational studies have suggested a potential risk of arrhythmias (irregular heartbeats) in susceptible individuals. Discuss any history of heart rhythm problems with your doctor.
There are no specific routine blood tests required for tiotropium. However, your healthcare provider will likely monitor:
Tiotropium may cause dizziness or blurred vision in some patients. If you experience these side effects, do not drive or operate heavy machinery until you are sure you can perform these activities safely.
There is no direct chemical interaction between alcohol and tiotropium. However, alcohol can sometimes worsen the dehydration associated with dry mouth. Furthermore, excessive alcohol use can depress the respiratory drive, which is counterproductive for patients with COPD or asthma.
Tiotropium does not typically cause a 'withdrawal syndrome.' However, if you stop taking it suddenly, your lung function may decline, and your symptoms (shortness of breath, wheezing) are likely to return or worsen. Always consult your doctor before stopping any maintenance respiratory medication.
> Important: Discuss all your medical conditions, especially kidney disease, glaucoma, or prostate problems, with your healthcare provider before starting Tiotropium.
Cimetidine and Ranitidine: Some studies suggest that cimetidine (a common H2 blocker for heartburn) may interfere with the renal clearance of tiotropium by competing for the same transport mechanisms in the kidneys. This could potentially increase the levels of tiotropium in the blood, though the clinical significance of this for an inhaled drug is usually low.
Potassium Chloride Supplements: Anticholinergics can slow down the movement of the gastrointestinal tract. If a patient is taking solid-dose potassium supplements (tablets), the slower transit time can lead to localized irritation or ulceration in the esophagus or stomach. Liquid potassium is generally preferred if an interaction is suspected.
Antihistamines (First-Generation): Drugs like diphenhydramine (Benadryl) or chlorpheniramine have significant anticholinergic properties. Using these alongside tiotropium increases the 'anticholinergic burden,' which is particularly dangerous for elderly patients, increasing the risk of falls, confusion, and dry mouth.
Tricyclic Antidepressants (TCAs): Medications like amitriptyline or nortriptyline also possess anticholinergic activity. Combining them with tiotropium may exacerbate side effects like constipation and rapid heart rate.
There are no known significant food interactions with inhaled tiotropium. Because the drug is inhaled and acts locally on the lung tissue, its absorption is not influenced by the presence of food in the stomach. Unlike some other medications, you do not need to worry about taking it on an empty or full stomach.
Belladonna / Henbane / Scopolamine: Any herbal supplement with 'atropine-like' or anticholinergic effects should be avoided, as they will worsen the side effects of tiotropium.
St. John's Wort: While St. John's Wort affects many drugs metabolized by the liver, its impact on tiotropium is minimal because tiotropium is primarily cleared by the kidneys.
Tiotropium is not known to significantly interfere with common laboratory tests, such as blood glucose, liver enzymes, or electrolyte panels. However, always inform your lab technician of all medications you are taking.
> Important: Tell your doctor about ALL medications, including over-the-counter cold medicines, sleep aids, supplements, and herbal products you are taking.
In these conditions, the benefits of tiotropium must be carefully weighed against the risks by a specialist:
Patients who are allergic to atropine or its derivatives should be considered at risk for cross-sensitivity to tiotropium. While not guaranteed, the structural similarities between these anticholinergic molecules mean the immune system may recognize both as threats. Always inform your doctor of any history of 'atropine' or 'belladonna' allergies.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of kidney disease or eye problems, before prescribing Tiotropium.
Elderly patients (65 and older) make up the largest group of tiotropium users.
Because the liver plays a minimal role in clearing tiotropium, no dosage adjustments are necessary for patients with hepatic impairment (Child-Pugh classes A, B, or C).
> Important: Special populations, particularly the elderly and those with kidney disease, require individualized medical assessment to ensure the safest possible treatment plan.
| Parameter | Value |
|---|---|
| Bioavailability | 20-33% (Inhaled) |
| Protein Binding | ~72% |
| Half-life | 24 - 44 hours |
| Tmax | 5 - 7 minutes (after inhalation) |
| Metabolism | CYP2D6, CYP3A4 (Minor) |
| Excretion | Renal 74% (of IV dose), Fecal (remainder) |
Tiotropium belongs to the therapeutic class of Bronchodilators and the pharmacologic class of Long-Acting Muscarinic Antagonists (LAMA). Related medications in the LAMA class include Umeclidinium, Aclidinium, and Glycopyrrolate.